北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2024 年度股东会、 2025 年第一次 A 股类别股东会议及 2025 年第一次 H 股类别股东会议的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 EUM E 3 F7 YUAN LAW OFFICES 北京 BEIJING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 致:杭州泰格医药科技股份有限公司 北京市嘉源律师事务所 关于杭州泰格医药科技股份有限公司 2024 年度股东会、2025年第一次 A 股类别股东会议及 2025 年第一次 H 股类别股东会议的法律意见书 嘉源(2025)-04-390 受杭州泰格医药科技股份有限公司(以下简称"公司")委托,北京市嘉源 律师事务所(以下简称"本所")指派律师出席公司 2024年度股东会、2025年 第一次 A 股类别股东会议及 2025 年第一次 H 股类别股东会议(以下简称"本次 股东会"),并依据《中华人民共和国公司法》(以下简称"《公司法》")、 《上市公司股东会规则》(以下简称"《股东会规则》 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）028 号 杭州泰格医药科技股份有限公司 2024 年度股东会、2025 年第一次 A 股类别股东会议及 2025 年第一 次 H 股类别股东会议决议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、会议召开情况 3、会议方式：本次股东会采取现场投票和网络投票相结合的方式 4、召集人：杭州泰格医药科技股份有限公司董事会 5、现场会议主持人：公司董事长叶小平先生 6、本次股东会会议的召集、召开与表决程序符合《公司法》、《上市公司股东会规则》、 《深圳证券交易所创业板股票上市规则》等法律、法规、规范性文件及《公司章程》的规 定。 1 二、会议出席情况 1、会议召开时间 现场会议召开时间为：2025年5月30日（星期五）上午10：00 网络投票时间：2025年5月30日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月30日上午9： 15—9：25，9：30—11：30和下午13：00—15：00；通过深圳证券交易所互联网投票系统进 行网络投票的具体时间为202 ...

Core Insights - The biovaccine sector saw a rise of 1.01%, ranking 10th among concept sectors, with 33 stocks increasing in value, including Wanbangde, which hit the daily limit, and notable gains from Guanhao Bio, Kexing Pharmaceutical, and Kanghua Bio, which rose by 8.88%, 7.40%, and 6.06% respectively [1][2] - The sector experienced a net inflow of 137 million yuan from main funds, with 31 stocks receiving net inflows, and five stocks exceeding 30 million yuan in net inflows, led by Fosun Pharma with 54.52 million yuan [2][3] Sector Performance - The top-performing sectors included pork (2.39%), chicken farming (1.94%), and innovative drugs (1.56%), while sectors like controllable nuclear fusion (-3.47%) and humanoid robots (-2.90%) faced declines [2] - The biovaccine sector's performance was supported by significant net inflows, with Wanbangde leading with a net inflow rate of 41.21%, followed by Haiwang Bio and Jindike [3] Stock Highlights - Key stocks in the biovaccine sector included: - Fosun Pharma: 5.23% increase, 54.52 million yuan net inflow, 2.82% turnover rate [3] - Taige Pharmaceutical: 3.60% increase, 44.07 million yuan net inflow, 3.92% turnover rate [3] - Wanbangde: 10.02% increase, 42.69 million yuan net inflow, 3.12% turnover rate [3] - Haiwang Bio: 3.57% increase, 34.73 million yuan net inflow, 5.19% turnover rate [3] - Guanhao Bio: 8.88% increase, 21.12 million yuan net inflow, 17.97% turnover rate [3]

Core Viewpoint - The biopharmaceutical and vaccine sector is experiencing growth driven by new drug approvals and increasing demand for vaccines, particularly in the context of an aging population and rising health awareness in China [2][3]. Group 1: Market Performance - As of May 30, 2025, the National Vaccine and Biotechnology Index (980015) increased by 0.44%, with notable gains from companies such as Jinbo Biotechnology (5.61%), Fosun Pharma (5.23%), and Zhaoyan New Drug (5.12%) [1]. - The Biopharmaceutical ETF (159657) rose by 0.64%, with the latest price at 0.63 yuan [2]. Group 2: New Drug Approvals - On May 29, the National Medical Products Administration released approvals for 11 new drugs, covering areas such as oncology and metabolic diseases, involving several domestic pharmaceutical companies [2]. - The approval of new drugs is expected to contribute positively to the performance of related companies [3]. Group 3: Industry Growth Potential - The demand for shingles vaccines is projected to grow significantly, with the Chinese market expanding from 0 in 2015 to 600 million yuan in 2021, and expected to reach 10.8 billion yuan by 2025 [2]. - Globally, the market for shingles vaccines is also expanding, with low vaccination rates in many countries indicating substantial future growth potential [2]. - Domestic vaccines are emerging, with two out of four globally approved shingles vaccines already available in China, suggesting increased market options and further industry development [2]. Group 4: Index Composition - The National Vaccine and Biotechnology Index (980015) consists of 50 companies involved in the biotechnology sector, reflecting the overall performance of quality listed companies in the industry [3]. - As of April 30, 2025, the top ten weighted stocks in the index include Fosun Pharma, Changchun High-tech, and Wantai Biological Pharmacy, collectively accounting for 63.18% of the index [3].

Group 1 - The Hong Kong stock market experienced a significant pullback on May 30, yet the innovative drug sector saw gains, with notable increases in stocks such as CSPC Pharmaceutical rising over 8% and others like Fosun Pharma and Zai Lab increasing over 5% [1] - The Hong Kong innovative drug ETF (159567) attracted over 200 million yuan in net inflows over the past 20 trading days, indicating high market interest [1] - The development of innovative drugs in China is driven by the transformation of generic drug companies and the emergence of biotech firms, supported by unmet clinical needs and the urgency of multinational pharmaceutical companies to fill their pipelines as they approach patent cliffs [1] Group 2 - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the international expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from both AI advancements and the introduction of new healthcare policies targeting high-priced innovative drugs [2] - The investment value of domestic innovative drug companies is increasingly highlighted in the current market environment, with recent sector pullbacks attributed more to external policy expectations rather than fundamental changes [2]

5月30日，港股市场低开低走，港股创新药板块逆势上涨。港股创新药指数成份股中，石药集团涨超 7%，复星医药、昭衍新药涨超4%，云顶新耀、先声药业涨超2%，泰格医药、诺诚健华、凯莱英涨超 1%。港股创新药ETF（159567）过去20个交易日获得超2亿元资金净流入，市场热度较高。 生物制药行业长期流传"双十"规律，即从新药研发开始到最终获批上市需要平均耗时十年，投入成本约 十亿美元，而实际成本往往数倍于此。除了周期长、成本高，制药还是一项高风险的事业，据业内估 计，全球新药研发的成功率仅在2%到15%之间。但人工智能拥有突破创新药"双十"限制的潜力，波士 顿咨询研究表示，AI生成的药物分子在I期临床试验中，成功率高达80%～90%，高于50%的历史平均水 平；而在II期临床试验中，成功率为40%，仍然位于历史区间上限。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中泰证券认为，创新药板块近期展现出强劲的投资价值，主要得益于三生制药与辉瑞 ...

Group 1: Resumption of Trading - Guangyang Co., Ltd. has terminated its plan to acquire 100% equity of Ningbo Yinqiu Technology through the issuance of shares and cash payment, leading to the resumption of its stock trading [1] Group 2: Equity Transfer, Buyback, and Private Placement - Shipu Testing plans to transfer a total of 9.5% of its shares to Zhongyiren Fund at a price of 20 yuan per share [2] - Qingniao Fire Protection has repurchased and canceled 12.2592 million restricted shares [2] - Tigermed has canceled 3.9225 million repurchased shares [3] - Shuanglin Co., Ltd. intends to raise no more than 1.5 billion yuan for projects related to rolling screw and joint module industrialization, high-precision CNC grinding machine expansion, and advanced technology research and application center construction [3] Group 3: External Investment and Daily Operations - Pingao Co., Ltd. has signed a contract for computing power resource services worth 397 million yuan [4] - Yiwei Communication plans to establish a wholly-owned subsidiary with an investment of 100 million yuan, focusing on artificial intelligence application software development [5] - Longjing Environmental Protection intends to acquire 20% equity of Jitai Intelligent for 75.075 million yuan [6] - Tianwei Video Technology has signed a data center service agreement with a client [7] - Fengmao Co., Ltd. plans to invest no more than 1.5 billion yuan to build an auto parts production base in Jiaxing [8] - ST Pioneer will have its stock delisted from other risk warnings starting June 3, 2025, with its stock name changing from "ST Pioneer" to "Pioneer New Materials" [8] - Maiwei Bio has received approval for the marketing of its product, Mai Li Sheng® [8] - Guangbai Co., Ltd. has completed the business registration of its duty-free goods company [9] - Zhuhai Guanyu has been selected by SAIC Volkswagen as a designated supplier for low-pressure lithium batteries [9] - Ningbo Fubang plans to transfer assets related to its aluminum profile business for 26.4579 million yuan [9] - Rongchang Bio has completed the issuance of H-shares [10] - Tebao Bio has received approval for the marketing of its growth hormone injection [10] - Zejing Pharmaceutical has received approval for the marketing of its drug, Hydrochloride Gikaxin [10] - Fengqian Technology has received record approval from the China Securities Regulatory Commission for its overseas H-share issuance [10] - Haida Group plans to distribute at least 30% of its average net profit in cash from 2025 to 2027 [10]

本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年5月29日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞 增 玉 先 生；獨 立 非 執 行 董 事 ...

泰格医药（300347）公告，本次注销的回购股份数量为392.25万股，占注销前公司总股本的0.45%。本 次实际回购注销金额为2亿元。注销完成后，公司总股本将由8.65亿股变更为8.61亿股。公司本次回购股 份注销事宜已于2025年5月29日办理完成。本次注销部分回购股份事项不会对公司的财务状况和经营成 果产生实质性影响，不存在损害公司利益及中小投资者利益的情形。 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）027 号 杭州泰格医药科技股份有限公司 关于部分回购股份注销完成暨股份变动的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述 或者重大遗漏负连带责任。 特别提示： 1、本次注销的回购股份数量为 3,922,520 股，占注销前公司总股本的 0.45%。本 次实际回购注销金额为 200,046,593.34 元。本次注销完成后，公司总股本将由 864,948,570 股变更为 861,026,050 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购股份注 销事宜已于 2025 年 5 月 29 日办理完成。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关法律 法规规定，现就本次杭州泰格医药科技股份有限公司（以下简称"公司"）部分回购股份 注销完成的具体情况公告如下： 一、回购股份的基本情况 公司分别于2024年2月6日、2024年4月12日及2024年4月30日召开的第五届董事会 第四次会议、第五届董事会第七次会议、2024年第二次临时股东大会、2024年第一次 ...